NDAINTRAVENOUSPOWDERPriority Review
Approved
Aug 2014
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Priority Review
ORBACTIV (oritavancin) by CorMedix is cytochrome p450 2c19 inhibitors [moa]. First approved in 2014.
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORBACTIV (oritavancin) is a lipoglycopeptide antibiotic administered intravenously as a powder formulation. It inhibits bacterial cell wall synthesis through CYP2C19 inhibition and is indicated for acute bacterial skin and skin structure infections (ABSSSI). The drug targets hospitalized patients with serious gram-positive infections including methicillin-resistant Staphylococcus aureus (MRSA).
$0.231MPart D
PeakStable
8.7 years to LOEProduct is at peak lifecycle stage with minimal Part D penetration ($231K, 69 claims in 2023), indicating niche positioning and likely small, specialized commercial team focused on hospital and infectious disease channels.
Mechanism of Action
Cytochrome P450 2C19 Inhibitors
Pharmacologic Class:
Lipoglycopeptide Antibacterial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ORBACTIV offers limited near-term career growth opportunity with zero linked job openings and a small, niche commercial footprint ($231K in Part D spending). Roles are concentrated in hospital-based specialty sales and medical affairs serving infectious disease specialists and hospital pharmacy committees.
Hospital Account Manager
Worked on ORBACTIV at CorMedix? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.